The global pemetrexed diacid market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing number of cancer cases and rising awareness about cancer treatment. Pemetrexed diacid is used for treating mesothelioma, NSCLC, and other types of cancers. It is also used for preventing recurrence in patients with NSCLC who have undergone surgery or radiation therapy. The global pemetrexed diacid market by type includes 100mg injection, 200mg injection, 300mg injection, 500mg injection; by application includes mesothelioma and no small cell lung cancer; by region includes North America (US & Canada), Latin America (Mexico & Brazil), Europe (Germany & France), Asia Pacific (China & Japan) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of cancer globally is one of the major factors driving the growth of the Pemetrexed Diacid market.
- Increasing number of cancer cases in developing countries such as China and India are also driving the growth of this market.
- Rising awareness about cancer and its treatment options among people is also fueling the growth of this market.
- Technological advancements in drug discovery and development are expected to provide new opportunities for companies operating in this market.
Industry Growth Insights published a new data on “Pemetrexed Diacid Market”. The research report is titled “Pemetrexed Diacid Market research by Types (100mg Injection, 200mg Injection, 300mg Injection, 500mg Injection), By Applications (Mesothelioma, Non-Small Cell Lung Cancer), By Players/Companies Eli Lilly and Company, Natco Pharma Ltd, United Biotech India Pvt.Ltd., Actiza Parma, Beacon Pharma, Chemotherapy, Onkos, Emcure, Cytotoxic, Pemgem, Lianyungang Tengfa Bio-tech Co., Ltd., Nanjing Pharmaceutical Factory Co., Ltd., Qilu Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pemetrexed Diacid Market Research Report
By Type
100mg Injection, 200mg Injection, 300mg Injection, 500mg Injection
By Application
Mesothelioma, Non-Small Cell Lung Cancer
By Companies
Eli Lilly and Company, Natco Pharma Ltd, United Biotech India Pvt.Ltd., Actiza Parma, Beacon Pharma, Chemotherapy, Onkos, Emcure, Cytotoxic, Pemgem, Lianyungang Tengfa Bio-tech Co., Ltd., Nanjing Pharmaceutical Factory Co., Ltd., Qilu Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Pemetrexed Diacid Market Report Segments:
The global Pemetrexed Diacid market is segmented on the basis of:
Types
100mg Injection, 200mg Injection, 300mg Injection, 500mg Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Mesothelioma, Non-Small Cell Lung Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Natco Pharma Ltd
- United Biotech India Pvt.Ltd.
- Actiza Parma
- Beacon Pharma
- Chemotherapy
- Onkos
- Emcure
- Cytotoxic
- Pemgem
- Lianyungang Tengfa Bio-tech Co., Ltd.
- Nanjing Pharmaceutical Factory Co., Ltd.
- Qilu Pharma
Highlights of The Pemetrexed Diacid Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg Injection
- 200mg Injection
- 300mg Injection
- 500mg Injection
- By Application:
- Mesothelioma
- Non-Small Cell Lung Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pemetrexed Diacid Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pemetrexed diacid is a chemotherapy drug used to treat cancer. It works by stopping the growth of cancer cells.
Some of the major companies in the pemetrexed diacid market are Eli Lilly and Company, Natco Pharma Ltd, United Biotech India Pvt.Ltd., Actiza Parma, Beacon Pharma, Chemotherapy, Onkos, Emcure, Cytotoxic, Pemgem, Lianyungang Tengfa Bio-tech Co., Ltd., Nanjing Pharmaceutical Factory Co., Ltd., Qilu Pharma.
The pemetrexed diacid market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pemetrexed Diacid Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pemetrexed Diacid Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pemetrexed Diacid Market - Supply Chain
4.5. Global Pemetrexed Diacid Market Forecast
4.5.1. Pemetrexed Diacid Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pemetrexed Diacid Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pemetrexed Diacid Market Absolute $ Opportunity
5. Global Pemetrexed Diacid Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pemetrexed Diacid Market Size and Volume Forecast by Type
5.3.1. 100mg Injection
5.3.2. 200mg Injection
5.3.3. 300mg Injection
5.3.4. 500mg Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pemetrexed Diacid Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pemetrexed Diacid Market Size and Volume Forecast by Application
6.3.1. Mesothelioma
6.3.2. Non-Small Cell Lung Cancer
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pemetrexed Diacid Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pemetrexed Diacid Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pemetrexed Diacid Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pemetrexed Diacid Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pemetrexed Diacid Demand Share Forecast, 2019-2026
9. North America Pemetrexed Diacid Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pemetrexed Diacid Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pemetrexed Diacid Market Size and Volume Forecast by Application
9.4.1. Mesothelioma
9.4.2. Non-Small Cell Lung Cancer
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pemetrexed Diacid Market Size and Volume Forecast by Type
9.7.1. 100mg Injection
9.7.2. 200mg Injection
9.7.3. 300mg Injection
9.7.4. 500mg Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pemetrexed Diacid Demand Share Forecast, 2019-2026
10. Latin America Pemetrexed Diacid Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pemetrexed Diacid Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pemetrexed Diacid Market Size and Volume Forecast by Application
10.4.1. Mesothelioma
10.4.2. Non-Small Cell Lung Cancer
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pemetrexed Diacid Market Size and Volume Forecast by Type
10.7.1. 100mg Injection
10.7.2. 200mg Injection
10.7.3. 300mg Injection
10.7.4. 500mg Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pemetrexed Diacid Demand Share Forecast, 2019-2026
11. Europe Pemetrexed Diacid Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pemetrexed Diacid Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pemetrexed Diacid Market Size and Volume Forecast by Application
11.4.1. Mesothelioma
11.4.2. Non-Small Cell Lung Cancer
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pemetrexed Diacid Market Size and Volume Forecast by Type
11.7.1. 100mg Injection
11.7.2. 200mg Injection
11.7.3. 300mg Injection
11.7.4. 500mg Injection
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Atractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pemetrexed Diacid Demand Share, 2019-2026
12. Asia Pacific Pemetrexed Diacid Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pemetrexed Diacid Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pemetrexed Diacid Market Size and Volume Forecast by Application
12.4.1. Mesothelioma
12.4.2. Non-Small Cell Lung Cancer
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pemetrexed Diacid Market Size and Volume Forecast by Type
12.7.1. 100mg Injection
12.7.2. 200mg Injection
12.7.3. 300mg Injection
12.7.4. 500mg Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pemetrexed Diacid Demand Share, 2019-2026
13. Middle East & Africa Pemetrexed Diacid Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pemetrexed Diacid Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pemetrexed Diacid Market Size and Volume Forecast by Application
13.4.1. Mesothelioma
13.4.2. Non-Small Cell Lung Cancer
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pemetrexed Diacid Market Size and Volume Forecast by Type
13.7.1. 100mg Injection
13.7.2. 200mg Injection
13.7.3. 300mg Injection
13.7.4. 500mg Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pemetrexed Diacid Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pemetrexed Diacid Market: Market Share Analysis
14.2. Pemetrexed Diacid Distributors and Customers
14.3. Pemetrexed Diacid Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly and Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Natco Pharma Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. United Biotech India Pvt.Ltd.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Actiza Parma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Beacon Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Chemotherapy
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Onkos
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Emcure
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Cytotoxic
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pemgem
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Lianyungang Tengfa Bio-tech Co., Ltd.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Nanjing Pharmaceutical Factory Co., Ltd.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Qilu Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook